To the Editor: Unbundling blood products from diagnosis-related group–based comprehensive reimbursement for medical procedures, along with establishing Medicare reimbursement schedules for blood products on the basis of current costs rather than historical charges, would provide some relief from the financial crisis in the blood industry that Klein et al. (Oct. 12 issue)1 describe. However, inefficiencies of the blood market that the authors also describe would remain. These include the monopsonistic structure of the market, which limits blood suppliers’ pricing power and, consequently, their reserve capacity to respond to future biologic threats to products that are inherently vulnerable to them. The . . .

中文翻译：

---

美国血液系统的可持续性危机

致编辑：将血液制品与基于诊断相关的基于群体的医疗程序综合报销分开，并根据当前成本而不是历史费用制定血液制品的医疗保险报销时间表，将在一定程度上缓解美国金融危机的影响。克莱因等人的血液工业。（10月12日号）1 描述。然而，作者也描述的血液市场效率低下的问题仍然存在。其中包括市场的垄断结构，这限制了血液供应商的定价能力，从而限制了他们应对未来对他们本身脆弱的产品的生物威胁的储备能力。这 。。。